Leap Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cypherpunk Technologies

12/08/2024 15:37

* Leap Therapeutics Inc  LPTX.OQ  reported a quarterly
adjusted
loss of 52 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -91 cents.  The mean expectation of
four analysts for the quarter was for a loss of 43 cents per
share. Wall Street expected results to range from -47 cents
to -35 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Leap Therapeutics Inc's reported EPS for the quarter was a
loss
of 52 cents​.
    * The company reported a quarterly loss of $20.36 million.
    * Leap Therapeutics Inc shares had risen by 25.8% this
quarter and
lost 40.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Leap Therapeutics
Inc is $12.00 
This summary was machine generated from LSEG data August 12 at
02:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.43          -0.52          Missed
 Mar. 31 2024      -0.58                         
 Dec. 31 2023      -0.55                         
 Sep. 30 2023      -0.58          -0.51          Beat